NxStage Medical — Q1 2008 Earnings Presentation
18 slides from NxStage Medical's earnings presentation, May 12, 2008
Slide 1: NxStage Medical Q1'08 Earnings Conference Call
NxStage Medical Q1'08 Earnings Conference Call May 12, 2008
Slide 2: Safe Harbor
2 Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of NxStage Medical, Inc. (or "NxStage" or "the Company") as of the date of this presentation and are naturally subject to uncertainty a
Slide 3: The New NxStage: 6 Months Post Medisystems Acquisition
3 The New NxStage: 6 Months Post Medisystems Acquisition Agenda Q1'08 Results Review of Three Markets and Outlook Vision for 2011
Slide 4: Q1'08 Results
4 Medisystems integration going well Strong revenue performance Gross margin improvement on track Distribution costs improving ahead of plan Home patient growth still unpredictable Solid financial performance in Q1 Q1'08 Results
Slide 5: Non-GAAP Disclosure
Non-GAAP Disclosure 5 During this call we will be referring to non- GAAP financial measures. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is avai
Slide 6: Reporting Going Forward
6 Reporting Going Forward Two segments System One Segment = NxStage pre Medisystems In-center Segment = Medisystems Three markets System One Segment Home Critical Care In-center Segment Medisystems Adjusted EBITDA Valuable to understanding our business performance
Slide 7: Q1'08 Financial Results
7 Q1'08 Financial Results Actual Guidance Revenue $31 MM $29-31 MM Net Loss $(13.9) MM $(14-16) MM Total Patients 2481 2523-2598 Net New Patients 258 300-375 Total Centers 355 354-364 New Centers 21 20-30 Adjusted EBITDA* $(8.3) MM *Adjusted EBITDA is defined as EBITDA adjusted for stock based compe
Slide 8: Q1'08 Encouraging Cost Progress
8 Q1'08 Encouraging Cost Progress Q1 '07 Q1 '08 Gross Margin - -18% 13% NxStage Product Distribution 28% 21% Adjusted EBITDA $(10.7)MM $(8.3)MM All Tracking at or Ahead of Plan
Slide 9: Year End Guidance
9 Year End Guidance FY '08 Revenue $130 - $135 MM Net Loss $(52) - $(56) MM Adjusted EBITDA $(28) - $(31) MM Home Patients 3100 - 3500
Slide 10: NxStage: Complementary Markets
10 NxStage: 3 Complementary Markets Delivers expected financial results Provides necessary flexibility Three growth opportunities - less dependent on any one market Cash required relatively insensitive to growth rate Clear growth opportunities for each market New products New markets
Slide 11: $1.6B Direct Market Opportunity
11 $1.6 B Direct Market Opportunity* In-Center Home Critical Care Total Annual US Potential Market* $500 MM $1 B $100 MM Key Growth Strategy New Products Market Expansion Market Conversion 2007 Sales $58 MM $30 MM $14 MM 2007 to 2011 Growth Target 2X 4-6X 2-3X International Is in Our Plans...Not Yet
Slide 12: In-Center - Medisystems
12 Competitive scale and infrastructure Longstanding reputation for high quality Significant product market share Potential to unlock more value In-Center - Medisystems
Slide 13: In-Center: Future
13 Growth from proprietary product pipeline Streamline Buttonhole Other products in development NxStage customer relationships Better positioned to communicate MDS product value Clinical Advantages Cost Savings Differentiated products improve performance 2007 to 2011 growth target - 2X In-Center: Fu
Slide 14: Home: Accomplishments
14 Market opportunity validation 19 geographies > 5% penetration 4 geographies 10 - 17% penetration Solid equipment reliability Pureflow More water treatment locations than anyone COGS reduction projects on track Reducing manufacturing cost Collaboration with vendors Lower cost material sources Home
Slide 15: Home: Expanding the Market
15 Home: Expanding the Market Develop large successful programs Grow clinical evidence Strong independent data validates Home Hemodialysis NxStage survival data FREEDOM interim analysis - QOL Improve reimbursement Medicare - reduce burden and improve predictability Training reimbursement needs to al
Slide 16: Critical Care: Hidden Asset
16 Estimated 25% of installed machines in US 31% YOY increase in machine placements 7 of top 10 US hospital systems already users Evaluation success rate >80% Competitive advantages Simplicity of use for nursing staff Very strong cost position from our scale Critical Care: Hidden Asset
Slide 17: Critical Care Future
17 Critical Care Future Market conversion opportunity Product evolution Product line expansion 2007 to 2011 growth target - 2-3X
Slide 18: Delivering Solid Financial Performance in Three Markets
18 Innovative Technology Market Experience Clinical Value Delivering Solid Financial Performance in Three Markets NxStage 2011